Recombinant zoster vaccine (RZV/Shingrix) two-dose series for adults 50 or older. First dose at age 50, second dose 2-6 months later. Over 90% efficacy against herpes zoster. Also recommended for immunocompromised adults 19 or older.
Enter the values for the scenario you are assessing. Recombinant zoster vaccine (RZV/Shingrix) two-dose series for adults 50 or older. First dose at age 50, second dose 2-6 months later. Over 90% efficacy against herpes zoster. Also recommended for immunocompromised adults 19 or older. Use the shingrix shingles vaccine result to inform your calculation.